What: Shares of Alkermes (NASDAQ:ALKS), a global biopharmaceutical company developing therapies to treat a range of diseases and disorders, jumped as much as 11% after reporting positive top-line results from a late-stage study involving experimental intramuscular injection aripiprazole lauroxil for the treatment of schizophrenia. Shares have since cooled and are up less than 4% as of this writing.

So what: According to Alkermes' press release, patients taking the once-monthly treatment, either in a 441 mg or 882 mg dose, "demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12 compared to placebo." On top of meeting its primary endpoint, aripiprazole lauroxil also met its secondary endpoint of improvement from baseline in the Clinical Global Impression – Improvement Scale at week 12. Following this data, Alkermes is merely dotting its I's and crossing its T's in preparation for a new drug application filing next quarter. The press release also notes that the company will release its full phase 3 data on the drug at an upcoming medical conference.

Now what: It's always a bit tough to get too excited when you don't have the full data set in front of you, but as far as this is set to become an additional long-term injectable dosing option for schizophrenia patients this looks like a winner. The therapy was well-tolerated, safe, and it met both its primary and secondary endpoint, so I'm certainly leaning toward it having a better chance of being approved than rejected by the Food and Drug Administration at this point in time.

Alkermes itself is a really interesting case wherein a number of mid-cap and larger biopharmaceutical companies are moving their pipeline focus onto rare diseases, it's pushing back into the large chronic disease market. The company is profitable and it has a healthy and growing portfolio and pipeline. Long story short, I won't beat around the bush about recommending you get Alkermes on your watchlist and would suggest biotech-savvy investors dive more deeply into this company when they have the chance.

Alkermes may have popped today, but it'll likely be hard-pressed to keep pace with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers